跳至主要内容
临床试验/CTIS2024-514602-31-00
CTIS2024-514602-31-00进行中(未招募)1 期

ong-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease - AERD-COV19

niwersytet Jagiellonski Collegium Medicum0 个研究点目标入组 76 人开始时间: 2024年5月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
76

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • INCLUSION CRITERIA FOR AERD PATIENTS:* signed informed consent form * 18-70 years old AERD patients with baseline FEV1 of at least 70% of the predicted value on the challenge/desensitization day * no pregnancy, higly effective contraception must be used, INCLUSION CRITERIA FOR HEALTHY CONTROL: * signed informed consent form * 18-70 years old and healthy condition * no asthma

排除标准

  • failure of the circulatory and respiratory system, liver, kidneys and other vital organs, diabetes, cancer, systemic diseases of connective tissue, infectious diseases, coagulation disorders, active peptic ulcer disease, any active bleeding process., Use of drugs that interact with aspirin, use of intoxicants, alcohol abuse, active and passive smoking, pregnancy, lactation, hypersensitivity to the active substance or any of the excipients

研究者

发起方
niwersytet Jagiellonski Collegium Medicum

相似试验